Cancer Cachexia - A Pipeline Analysis Report

Overview of the drug development pipeline for cancer cachexia

Cachexia is a progressive wasting syndrome, characterized by an unwanted weight loss in patients suffering from various chronic and lifestyle diseases including acquired immunodeficiency syndrome, diabetes, hormonal deficiency, cancer, and anorexia nervosa. Cachexia also involve conditions such as asthenia, fatigue, and muscle atrophy anemia. Technavio’s market research analysts have predicted that with the introduction of β-Hydroxy- β-methylbutyrate (HMB) and administration of appetite stimulants as some of the most promising approaches to treat cancer cachexia, the cancer cachexia market value will witness growth in the forthcoming years.

According to this pipeline analysis report, most of the drug development molecules in the pipeline are being produced under the phase II and pre-clinical drug development stages. The pipeline landscape in the pipeline analysis report mentions the percentage of drug development molecules that are under phase I, phase III, and discovery stage.

Cancer cachexia market share: Companies covered

Based on the cancer cachexia industry analysis, this pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of cancer cachexia. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies. This factor will positively impact the cancer cachexia market growth

Some of the companies covered in this pipeline analysis report are –

• AVEO Oncology
• Extend Biosciences
• Novartis

Therapeutic assessment of the drug development pipeline for cancer cachexia by route of administration

• Oral
• Subcutaneous injection
• Intravenous

The oral route of administration (ROA) involves the administration of drug substances through the mouth cavity. It has been observed that the majority of total therapeutics are being developed for oral administration.

Therapeutic assessment of the drug development pipeline for cancer cachexia by therapeutic modality

• Small molecule
• Monoclonal antibody

According to this pipeline analysis report, the majority of molecules that are currently in the drug development pipeline for cancer cachexia are being developed as small molecules. Small molecules are chemically manufactured active substances that can enter the cells easily due to their low molecular weight.

Key questions answered in the report include

• What are the drug development molecules in the various development stages for cancer cachexia?
• What are the companies that are currently involved in the development of drug development molecules for cancer cachexia?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.